Navigation Links
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
Date:4/15/2008

the six-month placebo-controlled trial showed that FTY720 reduced relapse rates by more than 50% compared to placebo. Current first-line therapies for MS reduced relapse rates by 30-35% on average in two-year studies.

Among patients originally on placebo who converted to active therapy in the extension, 51% were free of relapses at three years. The figure at two years was 57%.

FTY720 has been generally well tolerated throughout the three years of the Phase II study and its extension, with the most common adverse events being nasopharyngitis, headache, fatigue and influenza. Increases in alanine aminotransferase (liver enzymes) were observed in 16% of patients. Dermatological screening of patients was implemented in the extension after a small number of cases of localized skin malignancies were reported.

Novartis continues to study FTY720 in an ongoing, blinded Phase III clinical trial program. This program includes comprehensive monitoring that will further assess and characterize the safety profile of FTY720. For more information about the clinical trial program, including eligibility criteria and location of U.S. study sites, patients can call the following toll-free number: 866-788-3930, or visit http://www.MSClinicalTrials.com.

MS is caused by the destruction of myelin, which helps neurons carry electrical signals in the brain. The disease causes problems with muscle control and strength, vision, balance, sensation and mental function. MS typically presents in relapsing forms involving acute self-limiting attacks of neurological dysfunction (or "relapses") followed by complete or partial restoration of functions.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "planned", "potential", "would", "encouraging", "expected", "commitment", "may", "continues", "will", or similar expressions, or by expre
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
2. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
3. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
4. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
5. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
6. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
7. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
8. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
9. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
10. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
11. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 The National Necrotizing ... Fernando Davila has been successfully treated for a life ... Dr, Anibal R. Gauto , Medical Director of Inpatient ... Eisenhower Medical Center in Rancho Mirage, California ... pioneered by Dr. John Crew at Seton Hospital ...
(Date:8/20/2014)... 2014 Research and Markets  has announced the ... report to their offering. Global Market Report ... Pralmorelin globally and regionally ( Europe , ... Latin America etc.). It captures Pralmorelin ... report focuses on three primary areas; manufacture methods & technology ...
(Date:8/20/2014)... , Aug. 20, 2014 Research ... the "Global Advanced Wound Care and Closure ... Size, Share, Global Trends, Company Profiles, Demand, Insights, ... - 2020" report to their offering. ... wound care and closure market (types, applications, end ...
Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
... Germany, January 18, 2012 Eppendorf AG ... to Bibby Scientific for use e.g. in their TC ... 7,074,367. Eppendorf utilizes the technology in its Eppendorf Mastercycler® ... models. Eppendorf AG, based in Hamburg, Germany, ...
... Takeda Pharmaceutical Company Limited ("Takeda", TSE: ... global workforce and consolidate site operations in order to ... than 70 countries, adapt to changing market conditions and ... as outlined in its 2011-2013 Mid-Range Plan (MRP). ...
Cached Medicine Technology:Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 2Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 3Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 4Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 5
(Date:8/20/2014)... 20, 2014 Today, Zane Benefits, ... publication of a new eBook, Affordable Care Act ... business owners feel uncertain about how the ACA ... their bottom line. , The new eBook outlines ... businesses navigate their upcoming health insurance decisions. , ...
(Date:8/20/2014)... Dennis Thompson HealthDay Reporter ... teen birth rates fell dramatically during the past two decades, ... new government report shows. An estimated 4 million fewer ... according to researchers from the U.S. Centers for Disease Control ... at me from the report," said Bill Albert, chief program ...
(Date:8/20/2014)... study of chronic users of codeine-containing cough syrups ... brain white matter and associates these changes with ... used diffusuion tensor imaging (DTI) (an MR imaging ... white matter integrity of chronic CCS users. Deficits ... including the inferior fronto-occipital fasciculus, which other studies ...
(Date:8/20/2014)... -- Loss of brain cells that act as a ... trouble falling and staying asleep, a new study suggests. ... severe and often results in nighttime confusion and wandering, ... from the Rush Memory and Aging Project, which includes ... are being followed until death, at which point their ...
(Date:8/20/2014)... Park Cities Pet Sitter , Inc. has announced their ... drive that benefits the animal shelter and rescue communities. ... the Humane Society of the United States’ Animal Shelter Appreciation ... As part of their participation, Park Cities Pet Sitter plans ... Presents 4 Pets drive from their client base, as well ...
Breaking Medicine News(10 mins):Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 2Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 3Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4
... in the search for new Alzheimer,s,drugs, BIRMINGHAM, ... not-for-profit organization that conducts basic and applied,research in ... development --,today announced it has received funding from ... small molecules that activate Nuclear,Factor-kB (NF-kB)--a transcription factor ...
... -, NEW YORK, Oct. 1 American Media, Inc. (AMI) ... Form 10-Q,for the quarterly period ended June 30, 2007. In the ... first quarter of fiscal 2007 were $121.8 million, as ... 2006, representing a 5.6% increase., ...
... A visionary leader, Dr.,Maria Cristina Escobar Fritzsche ... contributions to the prevention and control of ... Pan American Sanitary Conference,proceedings today. The Abraham ... bestowed upon creative leaders whose commitment to,public ...
... 1. Organizations Issue Comprehensive Guidelines for Treating Low Back Pain ... , (Clinical Guidelines, p. 487.) (NOTE: This article is ... A separate news release will be issued.) , ... at Suppressing Hepatitis B Virus , A 52-week, randomized ...
... Flextronics International,Ltd. (Nasdaq: FLEX ) announced ... Corporation (NYSE: SLR ) creating the most ... vertically integrated,electronics manufacturing services ("EMS"). As a ... worldwide,EMS capabilities, from design resources to end-to-end vertically ...
... has named Glenn Adriance as Vice President of ... proven track record of developing, implementing,and managing effective ... "Glenn brings a wealth of experience to ... am pleased to welcome Glenn to the Mesa ...
Cached Medicine News:Health News:Southern Research Institute's Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding 2Health News:Southern Research Institute's Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding 3Health News:American Media Operations, Inc. Files Form 10-Q For First Quarter 2007 2Health News:Inter-American Leadership Award Bestowed Upon Chilean Chronic Disease Expert 2Health News:Annals of Internal Medicine tip sheet for Oct. 2 2Health News:Flextronics Completes Acquisition of Solectron 2Health News:Flextronics Completes Acquisition of Solectron 3Health News:Flextronics Completes Acquisition of Solectron 4Health News:Flextronics Completes Acquisition of Solectron 5
... the world's first directly illuminated, hand-held ... tradition of bringing superior ophthalmic technology ... keeping with that tradition, Welch Allyn ... Ophthalmoscope. With its newly designed precision ...
... The TOPCON 3D+ ALE-3700/3700PC/3700CF patternless processing system ... frame, quickly, accurately and with the convenience ... the 3D+ FR-20 Frame Reader, advanced processing ... is available with a polycarbonate feature (ALE-3700 ...
Inquire...
... Model II, is very simple to use ... obtained because it is only necessary to ... with internal reading scales then indicating the ... Since displacements between the centers of spectacle ...
Medicine Products: